| Literature DB >> 26932231 |
G Schiechl1, F J Hermann1, M Rodriguez Gomez1, S Kutzi1, K Schmidbauer1, Y Talke1, S Neumayer1, N Goebel1, K Renner1, H Brühl2, H Karasuyama3, K Obata-Ninomiya3, K Utpatel4, M Evert4, S W Hirt5, E K Geissler6, S Fichtner-Feigl6,7, M Mack1,7.
Abstract
Fibrosis is a major component of chronic cardiac allograft rejection. Although several cell types are able to produce collagen, resident (donor-derived) fibroblasts are mainly responsible for excessive production of extracellular matrix proteins. It is currently unclear which cells regulate production of connective tissue elements in allograft fibrosis and how basophils, as potential producers of profibrotic cytokines, are involved this process. We studied this question in a fully MHC-mismatched model of heart transplantation with transient depletion of CD4(+) T cells to largely prevent acute rejection. The model is characterized by myocardial infiltration of leukocytes and development of interstitial fibrosis and allograft vasculopathy. Using depletion of basophils, IL-4-deficient recipients and IL-4 receptor-deficient grafts, we showed that basophils and IL-4 play crucial roles in activation of fibroblasts and development of fibrotic organ remodeling. In the absence of CD4(+) T cells, basophils are the predominant source of IL-4 in the graft and contribute to expansion of myofibroblasts, interstitial deposition of collagen and development of allograft vasculopathy. Our results indicated that basophils trigger the production of various connective tissue elements by myofibroblasts. Basophil-derived IL-4 may be an attractive target for treatment of chronic allograft rejection. © Copyright 2016 The American Society of Transplantation and the American Society of Transplant Surgeons.Entities:
Keywords: basic (laboratory) research/science; fibrosis; heart (allograft) function/dysfunction; heart transplantation/cardiology; immune regulation; immunobiology; immunosuppression/immune modulation; rejection: chronic; signaling/signaling pathways
Mesh:
Substances:
Year: 2016 PMID: 26932231 DOI: 10.1111/ajt.13764
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 8.086